The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict STAAR Surgical's revenues will increase 9.1% and EPS will expand 33.3%.
The average estimate for revenue is $17.4 million. On the bottom line, the average EPS estimate is $0.04.
Last quarter, STAAR Surgical tallied revenue of $18.0 million. GAAP reported sales were 16% higher than the prior-year quarter's $15.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.08. GAAP EPS of $0.01 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 70.2%, 10 basis points worse than the prior-year quarter. Operating margin was 6.0%, 420 basis points better than the prior-year quarter. Net margin was 2.6%, 110 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $70.7 million. The average EPS estimate is $0.16.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 81 members out of 91 rating the stock outperform, and 10 members rating it underperform. Among 30 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 26 give STAAR Surgical a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is outperform, with an average price target of $8.00.
Is STAAR Surgical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add STAAR Surgical to My Watchlist.